Atlas Blog

Expert-led insights on
FDA compliance

Insights on FDA inspections, compliance strategy, and regulatory intelligence from the Atlas team.

Where to Find FDA 483 Reports (and How to Read One)

There are three routes to an FDA Form 483: FDA's FOIA electronic reading room, a FOIA request, or a searchable database. This guide compares them on coverage, wait time and search, then explains how to read a 483 once you have it, with three recent examples.

Read article

Computerized system validation: OQ audit trail tests for life sciences

Computerized system validation is the documented, risk-based evidence that a regulated computer system works as intended and keeps its data trustworthy. This guide covers the expectations in FDA's CSA guidance, Part 11, EMA and ICH E6(R3), a seven-step lifecycle, concrete OQ audit trail test cases, vendor and periodic review controls, and Atlas data on how often FDA cites computerized systems and data integrity.

FDA 483 vs warning letter: the 15 working day response windows and what 4,584 Form 483s from 2025 show

Regulatory Intelligence

FDA 483 vs warning letter: who gets 15 working days to respond?

A Form FDA 483 is the investigator's list of observations at the close of an inspection. A warning letter is a formal advisory FDA issues later, after review, when it judges violations significant. This guide explains the 15 business day response window for each, how FDA escalates and closes out warning letters, what Atlas data on 4,584 Form 483s from 2025 shows, and how to write a response that survives verification.

Regulatory Intelligence

Chlorthalidone recall 2026: two dissolution failures, the lots, and the manufacturer's FDA record

Chlorthalidone 25 mg tablets made by Inventia Healthcare in India and distributed by Rising Pharma were recalled twice in 2026, in June and September, for failed dissolution specifications. This piece covers the lots, what a dissolution failure means, the manufacturer's FDA inspection and Form 483 history, and what quality teams should check.

Compliance

CSA vs CSV for life sciences: five stages inspectors can trace

Computer System Validation proves software works through specifications and scripted tests; Computer Software Assurance sizes the effort to risk. This guide covers FDA's four-step CSA approach, a five-stage governance model, how to apply it to EBR, MES and LIMS, hybrid strategies, the records inspectors ask for, and how often FDA cites computerized-system controls.

Inspection Readiness

Mock FDA inspections: four formats for quality teams facing the 2026 QMSR

A mock FDA inspection tests your records, procedures, interviews and facility the way an investigator would, without regulatory authority. This guide covers choosing the right format, a ten-step sequence, the findings investigators cite most with Atlas data, converting findings into CAPA, and the 2026 QMSR changes for device mocks.

Regulatory Intelligence

Olympus FDA warning letter 2026: the six facilities, and the 483s behind it

Olympus received an FDA warning letter dated October 7, 2026 covering six facilities. This piece lays out the late-2025 Form 483s at each site, the regulations cited, the investigators involved, Hachioji's earlier warning-letter history, and what the pattern means for device quality teams.

Fresenius FDA warning letters 2026: what the Ogden and Melrose Park letters say, and the 483s behind them

Regulatory Intelligence

Fresenius Kabi FDA warning letter 2026: Melrose Park, the Ogden letter, and the 483s behind them

Two Fresenius facilities received FDA warning letters within four weeks of each other in 2026. This piece explains what the Ogden, Utah and Melrose Park, Illinois letters cite, the Form 483s and inspections that preceded them, the group's wider enforcement record, and what the two cases have in common.

Regulatory Intelligence

What Is an FDA Form 483? Observations, Responses, and What Happens Next

An FDA Form 483 is the list of inspectional observations an FDA investigator hands to management at the close of an inspection. This guide covers what a 483 contains, how many FDA issues each year, what a typical one looks like, how to respond within 15 business days, and how a 483 turns into a VAI, OAI, or warning letter.

What 438 FDA Refusal Letters Say.

Atlas

Regulatory Intelligence

FDA Complete Response Letters: What 438 Published CRLs Say About Facility Readiness

Every published FDA Complete Response Letter, classified against its own wording. Facility readiness appears in roughly half, the four sentences the agency reuses, the two ways teams misread the record, and six checks to run before filing.

Claude or OpenAI? Wrong Question.

Atlas

AI & Technology

Claude or OpenAI? Why the model is the easiest part of AI adoption in pharma quality.

About 25% of pharma and medical device organizations are piloting AI for regulatory and compliance review — but the model isn't the constraint. Legacy QMS data, process variation, and budget framing are where adoption stalls.

The QMS AI Rollout Checklist.

Atlas

AI & Technology

Rolling out an AI module in your QMS: what to look out for (the model is one of them)

Your QMS vendor just shipped an AI module, and the demo focused on the model. But infrastructure, change management, and QMS-ERP integration — the technologistics layer above the model — are where most AI rollouts in regulated quality functions succeed or fail.

When Your CEO Mandates AI.

Atlas

AI & Technology

Your CEO just mandated AI adoption. Here's the five-line memo your chief of QA-RA actually needs.

The CEO came back from a conference and wants an AI strategy for quality. The honest, board-ready version is 5 lines: one capability shipped, one pilot named, one thing you're explicitly not doing, your data integrity approach, and what you'll know by the next board meeting.

FDA Guidance Monitoring Database.

Atlas

Regulatory Intelligence

How an FDA Guidance Monitoring Database Reduces Inspection Risk?

Most FDA inspection risks come from missed guidance updates, fragmented monitoring, and lack of evidence that regulatory changes were tracked. A dedicated guidance monitoring database like Hedwig centralizes global guidance, tracks updates and withdrawals, and creates inspection-ready evidence of continuous monitoring.

From Reactive to Proactive Compliance.

Atlas

Inspection Readiness

What prevents teams from shifting from reactive to proactive compliance?

Every compliance team wants to be proactive. They want to spot changes early, assess impact quickly, and act before an investigator raises an issue.

FDA Audits for eLogs and eBatches.

Atlas

Inspection Readiness

Are pharma companies ready for FDA audits of eLogs and digital batch records?

The shift from paper to electronic logs (eLogs) and electronic batch records (eBMRs) is accelerating across pharma manufacturing.

Expert-led insights onFDA compliance

Where to Find FDA 483 Reports (and How to Read One)

Editor’s Picks

Preparing for FDA Pre-Approval Inspections: A Practical Guide

NAI, VAI, OAI: What Each FDA Inspection Classification Means

Preparing for FDA QSIT Inspections: What to Expect

FDA Warning Letter Database: How to Search It and Trace a Letter to Its 483

Computerized system validation: OQ audit trail tests for life sciences

FDA 483 vs warning letter: who gets 15 working days to respond?

Chlorthalidone recall 2026: two dissolution failures, the lots, and the manufacturer's FDA record

CSA vs CSV for life sciences: five stages inspectors can trace

Mock FDA inspections: four formats for quality teams facing the 2026 QMSR

Olympus FDA warning letter 2026: the six facilities, and the 483s behind it

Fresenius Kabi FDA warning letter 2026: Melrose Park, the Ogden letter, and the 483s behind them

What Is an FDA Form 483? Observations, Responses, and What Happens Next

FDA Complete Response Letters: What 438 Published CRLs Say About Facility Readiness

Claude or OpenAI? Why the model is the easiest part of AI adoption in pharma quality.

Rolling out an AI module in your QMS: what to look out for (the model is one of them)

Your CEO just mandated AI adoption. Here's the five-line memo your chief of QA-RA actually needs.

How an FDA Guidance Monitoring Database Reduces Inspection Risk?

What prevents teams from shifting from reactive to proactive compliance?

Are pharma companies ready for FDA audits of eLogs and digital batch records?

Expert-led insights on
FDA compliance